Atp7B is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ATPase 7B |
|---|
| Gene Symbol | ATP7B |
| Full Name | ATPase 7B (Copper Transporting ATPase) |
| Chromosome | 13q14.3 |
| NCBI Gene ID | 540 |
| OMIM | 606882 |
| Ensembl ID | ENSG00000130201 |
| UniProt ID | P35620 |
| Protein Length | 1465 amino acids |
| Molecular Weight | 157 kDa |
| Associated Diseases | Wilson Disease, Alzheimer's Disease, Parkinson's Disease |
ATP7B (ATPase 7B) encodes a P-type copper-transporting ATPase that plays a crucial role in copper homeostasis throughout the body. This membrane protein is essential for copper excretion into bile, incorporation of copper into ceruloplasmin, and delivery of copper to copper-dependent enzymes. ATP7B is primarily expressed in the liver but is also expressed in the brain, where it plays important roles in neuronal copper metabolism and neuroprotection.
The ATP7B protein belongs to the P-type ATPase family (ATPase 7 subfamily) and utilizes the energy from ATP hydrolysis to transport copper ions across cellular membranes. Mutations in ATP7B cause Wilson disease, a recessive genetic disorder characterized by excessive copper accumulation in the liver, brain, and other organs. Beyond Wilson disease, emerging research suggests ATP7B dysfunction may contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
ATP7B is a large transmembrane protein consisting of 1465 amino acids with a molecular weight of approximately 157 kDa. The protein contains several distinct structural domains:
¶ Transmembrane Domain
- 6-8 Transmembrane Helices: Form the copper translocation channel across the membrane
- Copper Binding Sites: Multiple CXXC motifs in the N-terminal domain that bind copper ions
- Channel Pore: Formed by transmembrane helices allowing copper passage
¶ Functional Domains
- N-terminal Metal-Binding Domain: Contains 6 copper-binding sites (MXHCXXC motifs)
- Phosphorylation Domain: Contains the conserved DKTGTLT motif essential for ATP hydrolysis
- Actuator Domain: Interacts with the phosphorylation domain to facilitate conformational changes
- ATP-binding Domain: Catalyzes ATP hydrolysis to provide energy for transport
ATP7B operates as a copper pump using the following mechanism:
- Copper Binding: Copper ions bind to the N-terminal metal-binding domain
- ATP Hydrolysis: ATP binding and hydrolysis induces conformational change
- Translocation: Copper is transported across the membrane
- Release: Copper is released into the bile or incorporated into ceruloplasmin
- Reset: The transporter returns to its original conformation
- Biliary Copper Excretion: Primary pathway for copper elimination from the body
- Ceruloplasmin Synthesis: Incorporates copper into ceruloplasmin (90% of plasma copper)
- Copper Delivery: Supplies copper to copper-dependent enzymes (cytochrome c oxidase, superoxide dismutase 1)
- Cellular Copper Homeostasis: Maintains intracellular copper balance
ATP7B shows tissue-specific expression:
- Liver: Highest expression - primary site of copper metabolism
- Brain: Neurons and glial cells, particularly in basal ganglia
- Kidney: Tubular cells
- Placenta: Trophoblast cells
- Lung: Epithelial cells
In hepatocytes, ATP7B localizes to the trans-Golgi network under normal copper conditions and redistributes to canalicular membranes when copper levels are elevated.
Wilson disease is caused by biallelic pathogenic variants in ATP7B, leading to:
- Liver Disease: Hepatitis, cirrhosis, hepatic failure
- Neurological Symptoms: Tremor, dysarthria, dystonia, parkinsonism
- Psychiatric Manifestations: Depression, psychosis, behavioral changes
- Kayser-Fleischer Rings: Copper deposition in Descemet's membrane
The neurological manifestations result from copper accumulation in the basal ganglia, particularly the putamen and globus pallidus.
ATP7B is implicated in Alzheimer's disease pathogenesis through several mechanisms:
- Copper Dysregulation: Altered ATP7B expression in AD brain
- Amyloid Processing: Copper interacts with Aβ and affects amyloid precursor protein processing
- Oxidative Stress: Copper homeostasis affects reactive oxygen species generation
- Tau Pathology: Copper influences tau phosphorylation and aggregation
Studies show increased ATP7B expression in AD hippocampus and cortex, potentially as a compensatory response to copper dysregulation.
ATP7B dysfunction may contribute to PD through:
- Metal Homeostasis: Altered copper handling in dopaminergic neurons
- Mitochondrial Function: Copper is essential for mitochondrial electron transport chain
- Alpha-Synuclein: Copper binding to α-syn affects its aggregation
- Levodopa Metabolism: Copper-dependent enzymes in dopamine biosynthesis
Emerging evidence links ATP7B to ALS:
- Copper Metabolism: Altered in ALS motor neurons
- SOD1 Maturation: ATP7B supplies copper to Cu/Zn superoxide dismutase
- Oxidative Stress: Copper homeostasis affects ROS metabolism
Current therapies targeting ATP7B include:
- Chelators: Penicillamine, trientine - promote copper excretion
- Zinc Salts: Inhibit intestinal copper absorption
- Liver Transplantation: For end-stage liver disease
ATP7B modulation strategies for AD and PD:
- Copper Modulators: Compounds that restore neuronal copper homeostasis
- Gene Therapy: AAV-mediated ATP7B delivery to brain
- Small Molecule Activators: Enhance ATP7B function in neurodegeneration
- Protein Stabilizers: Compounds that stabilize mutant ATP7B
Pharmaceutical approaches include:
- ATP7B-Specific Chelators: Targeted copper removal
- Pharmacological Chaperones: Stabilize misfolded ATP7B
- Neuronal Copper Delivery: Restore copper in specific brain regions
ATP7B knockout mice develop:
- Liver copper accumulation
- Hepatitis and cirrhosis
- Neurological abnormalities
- Reduced lifespan
Mouse models with human ATP7B mutations replicate:
- Wilson disease phenotype
- Copper metabolism abnormalities
- Neurological manifestations
ATP7B-related biomarkers include:
- Serum Ceruloplasmin: Decreased in Wilson disease
- 24-hour Urinary Copper: Elevated in Wilson disease
- Liver Copper Content: Diagnostic for Wilson disease
- CSF Copper: Altered in neurodegenerative diseases
ATP7B interacts with multiple pathways:
- Metal Metabolism: Central regulator of copper homeostasis
- Oxidative Stress Response: Copper-dependent ROS metabolism
- Autophagy-Lysosomal Pathway: Copper-induced autophagy
- Mitochondrial Function: Copper delivery to mitochondrial enzymes
- Neuroinflammation: Copper modulates microglial activation
The study of Atp7B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1. Lutsenko S, et al. (2007). "Function and regulation of human copper-transporting ATPases." Physiological Reviews. 87(3):1011-1046.
2. Bull PC, et al. (1993). "The Wilson disease gene is a putative copper transporting ATPase similar to the Menkes gene." Nature Genetics. 5(4):327-337.
3. Bandmann O, et al. (2015). "Wilson's disease and other neurological copper disorders." Lancet Neurology. 14(1):103-113.
4. Honer C, et al. (2021). "ATP7B and neurodegeneration: beyond Wilson disease." Journal of Neurochemistry. 158(2):255-267.
5. Cheng HM, et al. (2020). "Copper in Alzheimer's disease: implications for amyloid-beta and tau pathology." Free Radical Biology & Medicine. 158:1-13.
6. Davies KM, et al. (2013). "Copper pathology in neurodegenerative diseases." Acta Neuropathologica Communications. 1(1):81.
7. Montes S, et al. (2014). "Copper and copper proteins in Parkinson's disease." Journal of Neural Transmission. 121(8):899-905.
8. Gitlin JD (2003). "Wilson disease." Gastroenterology. 125(6):1868-1877.